About this episode

This episode discusses the 2026 pharmaceutical price increases and their implications for healthcare access and innovation.

I n early 2026, pharmaceutical manufacturers announced list price increases on at least 350 brand-name medications, continuing a pattern that affects treatments for cancer, COVID-19, migraines, and other conditions despite policy efforts to enhance affordability. This episode examines the scope of these hikes, notable examples such as Pfizer’s adjustments to Ibrance and Comirnaty, and the broader context of Medicare negotiations that provide relief for select drugs. Listeners will gain insights into the economic drivers, patient impacts, and potential long-term consequences for healthcare access and innovation.100

Topics covered

• healthcare costs
• pharmaceutical pricing
• patient access
• Medicare
• economic impact
• drug innovation

Keywords

• pharmaceuticals
• healthcare
• price increases
• Ibrance
• Comirnaty
• Medicare
• patient impact
• economic drivers

Mentioned in this episode

Organizations: Pfizer

Products: Ibrance, Comirnaty

More episodes of Pharmacology News

• Noribogaine (DMX-1001): A Neuroplastogen Breakthrough for Alcohol Use Disorder or Another Psychedelic Promise with Risks? · June 1, 2026 · 5 min
• The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 2 · May 26, 2026 · 5 min
• The Accidental Mind: Serendipity and the Birth of Modern Psychopharmacology part 1 · May 25, 2026 · 4 min
• Curcumin: Turmeric’s Golden Promise for Blood Sugar and Mood – Evidence, Arguments For and Against · May 21, 2026 · 6 min
• Dextromethorphan ( think cough syrup) for OCD: A Promising Glutamate-Targeted Augmentation Strategy? · May 20, 2026 · 7 min
• Antidepressants and Suicide Prevention: Lessons from Korea’s 2002 Prescription Restrictions · May 15, 2026 · 8 min

Explore listener stats, chart rankings, contacts and more on the Pharmacology News podcast page.